KR102254957B1 - 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드) - Google Patents
골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드) Download PDFInfo
- Publication number
- KR102254957B1 KR102254957B1 KR1020167015759A KR20167015759A KR102254957B1 KR 102254957 B1 KR102254957 B1 KR 102254957B1 KR 1020167015759 A KR1020167015759 A KR 1020167015759A KR 20167015759 A KR20167015759 A KR 20167015759A KR 102254957 B1 KR102254957 B1 KR 102254957B1
- Authority
- KR
- South Korea
- Prior art keywords
- gastrin
- bone
- hypergastrinemia
- cells
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 63
- YDZYKNJZCVIKPP-VWLOTQADSA-N netazepide Chemical compound CNC1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 YDZYKNJZCVIKPP-VWLOTQADSA-N 0.000 title claims abstract description 35
- 208000001132 Osteoporosis Diseases 0.000 title claims description 35
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title abstract description 341
- 108010052343 Gastrins Proteins 0.000 title abstract description 330
- 230000002265 prevention Effects 0.000 title abstract description 8
- 102100021022 Gastrin Human genes 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title description 31
- 229950010986 netazepide Drugs 0.000 title description 2
- 206010060377 Hypergastrinaemia Diseases 0.000 claims abstract description 167
- 208000020084 Bone disease Diseases 0.000 claims abstract description 41
- 239000002253 acid Substances 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 201000004535 ovarian dysfunction Diseases 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010033165 Ovarian failure Diseases 0.000 claims description 11
- 231100000539 ovarian failure Toxicity 0.000 claims description 11
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 230000001613 neoplastic effect Effects 0.000 claims description 6
- 229960000381 omeprazole Drugs 0.000 claims description 6
- 238000002651 drug therapy Methods 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 155
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 abstract description 106
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract description 82
- 230000001404 mediated effect Effects 0.000 abstract description 68
- 230000008685 targeting Effects 0.000 abstract description 52
- 239000003795 chemical substances by application Substances 0.000 abstract description 49
- 102000052874 Gastrin receptors Human genes 0.000 abstract description 38
- 238000000034 method Methods 0.000 abstract description 32
- 206010065687 Bone loss Diseases 0.000 abstract description 26
- 239000000203 mixture Substances 0.000 abstract description 11
- 230000032683 aging Effects 0.000 abstract description 5
- 102400000921 Gastrin Human genes 0.000 description 334
- 210000000988 bone and bone Anatomy 0.000 description 237
- 241001465754 Metazoa Species 0.000 description 171
- 238000009806 oophorectomy Methods 0.000 description 138
- 102000003982 Parathyroid hormone Human genes 0.000 description 132
- 108090000445 Parathyroid hormone Proteins 0.000 description 132
- 239000000199 parathyroid hormone Substances 0.000 description 132
- 229960001319 parathyroid hormone Drugs 0.000 description 132
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 125
- 230000001965 increasing effect Effects 0.000 description 91
- 210000004027 cell Anatomy 0.000 description 82
- 230000002611 ovarian Effects 0.000 description 80
- 239000000262 estrogen Substances 0.000 description 78
- 229940011871 estrogen Drugs 0.000 description 78
- 230000014509 gene expression Effects 0.000 description 71
- 210000000712 G cell Anatomy 0.000 description 69
- 239000011575 calcium Substances 0.000 description 64
- 230000007774 longterm Effects 0.000 description 63
- 230000002829 reductive effect Effects 0.000 description 63
- 229960001340 histamine Drugs 0.000 description 62
- 230000001054 cortical effect Effects 0.000 description 60
- 230000028327 secretion Effects 0.000 description 55
- 108010014095 Histidine decarboxylase Proteins 0.000 description 46
- 102100037095 Histidine decarboxylase Human genes 0.000 description 46
- 210000000963 osteoblast Anatomy 0.000 description 44
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 43
- 230000002496 gastric effect Effects 0.000 description 42
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 41
- 102000005962 receptors Human genes 0.000 description 41
- 108020003175 receptors Proteins 0.000 description 41
- 208000010392 Bone Fractures Diseases 0.000 description 40
- 230000004913 activation Effects 0.000 description 40
- 229910052791 calcium Inorganic materials 0.000 description 40
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 39
- 206010017076 Fracture Diseases 0.000 description 35
- 210000001185 bone marrow Anatomy 0.000 description 34
- 210000002997 osteoclast Anatomy 0.000 description 32
- 230000004075 alteration Effects 0.000 description 31
- 230000003247 decreasing effect Effects 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 29
- 230000037118 bone strength Effects 0.000 description 29
- 230000005764 inhibitory process Effects 0.000 description 28
- 210000004188 enterochromaffin-like cell Anatomy 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 238000010603 microCT Methods 0.000 description 26
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 26
- 230000000849 parathyroid Effects 0.000 description 25
- 108060001064 Calcitonin Proteins 0.000 description 24
- 102000055006 Calcitonin Human genes 0.000 description 23
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 23
- 229960004015 calcitonin Drugs 0.000 description 23
- 210000001685 thyroid gland Anatomy 0.000 description 23
- 238000010521 absorption reaction Methods 0.000 description 22
- 210000002784 stomach Anatomy 0.000 description 22
- 230000001009 osteoporotic effect Effects 0.000 description 21
- 210000002990 parathyroid gland Anatomy 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 229940088597 hormone Drugs 0.000 description 19
- 239000005556 hormone Substances 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- 210000000689 upper leg Anatomy 0.000 description 19
- 108091005932 CCKBR Proteins 0.000 description 18
- 230000037182 bone density Effects 0.000 description 18
- 230000010072 bone remodeling Effects 0.000 description 18
- 230000003915 cell function Effects 0.000 description 18
- ARLKVQYMFRECLV-JSGCOSHPSA-N (2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanamide Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(N)=O)=CNC2=C1 ARLKVQYMFRECLV-JSGCOSHPSA-N 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 16
- 230000007423 decrease Effects 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 210000003771 C cell Anatomy 0.000 description 15
- 230000018678 bone mineralization Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 14
- 230000011164 ossification Effects 0.000 description 14
- 208000006386 Bone Resorption Diseases 0.000 description 13
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 13
- 230000024279 bone resorption Effects 0.000 description 13
- 229960005309 estradiol Drugs 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 229940076279 serotonin Drugs 0.000 description 13
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 12
- 238000011533 pre-incubation Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 108010025832 RANK Ligand Proteins 0.000 description 11
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 11
- 230000033558 biomineral tissue development Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000004936 stimulating effect Effects 0.000 description 11
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 10
- 230000003491 cAMP production Effects 0.000 description 10
- 229930182833 estradiol Natural products 0.000 description 10
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000001000 micrograph Methods 0.000 description 9
- 230000000955 neuroendocrine Effects 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- -1 PTH1R Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 210000002449 bone cell Anatomy 0.000 description 8
- 230000037186 bone physiology Effects 0.000 description 8
- 230000004094 calcium homeostasis Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000013110 gastrectomy Methods 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000000877 morphologic effect Effects 0.000 description 8
- 210000004412 neuroendocrine cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 7
- 102100038595 Estrogen receptor Human genes 0.000 description 7
- 230000009858 acid secretion Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000002962 histologic effect Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 229910052762 osmium Inorganic materials 0.000 description 7
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 7
- 229940126409 proton pump inhibitor Drugs 0.000 description 7
- 239000000612 proton pump inhibitor Substances 0.000 description 7
- 238000007634 remodeling Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 6
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 6
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 6
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 6
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000043136 MAP kinase family Human genes 0.000 description 6
- 108091054455 MAP kinase family Proteins 0.000 description 6
- 108010016076 Octreotide Proteins 0.000 description 6
- 102000004067 Osteocalcin Human genes 0.000 description 6
- 108090000573 Osteocalcin Proteins 0.000 description 6
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- 229930003316 Vitamin D Natural products 0.000 description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000004097 bone metabolism Effects 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 108010038795 estrogen receptors Proteins 0.000 description 6
- 210000002406 gastrin-secreting cell Anatomy 0.000 description 6
- 210000004349 growth plate Anatomy 0.000 description 6
- 102000058004 human PTH Human genes 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 229960002700 octreotide Drugs 0.000 description 6
- 210000001711 oxyntic cell Anatomy 0.000 description 6
- 238000013001 point bending Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 235000019166 vitamin D Nutrition 0.000 description 6
- 239000011710 vitamin D Substances 0.000 description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 description 6
- 229940046008 vitamin d Drugs 0.000 description 6
- 108010038447 Chromogranin A Proteins 0.000 description 5
- 102000010792 Chromogranin A Human genes 0.000 description 5
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 5
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 5
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 5
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 5
- 208000029725 Metabolic bone disease Diseases 0.000 description 5
- 206010049088 Osteopenia Diseases 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000001195 anabolic effect Effects 0.000 description 5
- 210000002798 bone marrow cell Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 238000002224 dissection Methods 0.000 description 5
- 230000004821 effect on bone Effects 0.000 description 5
- 210000002745 epiphysis Anatomy 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 5
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229950003937 tolonium Drugs 0.000 description 5
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 5
- 210000001186 vagus nerve Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102100032187 Androgen receptor Human genes 0.000 description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 206010067994 Mucosal atrophy Diseases 0.000 description 4
- 108010016731 PPAR gamma Proteins 0.000 description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 108010080146 androgen receptors Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008412 bone pathophysiology Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 231100000344 non-irritating Toxicity 0.000 description 4
- 230000004072 osteoblast differentiation Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 229940043437 protein kinase A inhibitor Drugs 0.000 description 4
- 239000012656 protein kinase A inhibitor Substances 0.000 description 4
- 108010065251 protein kinase modulator Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011808 rodent model Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 4
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108010001789 Calcitonin Receptors Proteins 0.000 description 3
- 102100038520 Calcitonin receptor Human genes 0.000 description 3
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 3
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 208000006735 Periostitis Diseases 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000011496 cAMP-mediated signaling Effects 0.000 description 3
- 108060001061 calbindin Proteins 0.000 description 3
- 102000014823 calbindin Human genes 0.000 description 3
- 230000003913 calcium metabolism Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 230000003562 morphometric effect Effects 0.000 description 3
- 238000013425 morphometry Methods 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 210000003460 periosteum Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 102000035037 5-HT3 receptors Human genes 0.000 description 2
- 108091005477 5-HT3 receptors Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 108010051479 Bombesin Proteins 0.000 description 2
- 102000013585 Bombesin Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101710190440 Cytotoxin 1 Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000000543 Histamine Receptors Human genes 0.000 description 2
- 108010002059 Histamine Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020877 Hypertrophic osteoarthropathy Diseases 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 206010061363 Skeletal injury Diseases 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940124325 anabolic agent Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 2
- 230000009992 cAMP activation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000005115 demineralization Methods 0.000 description 2
- 230000002328 demineralizing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000004079 mineral homeostasis Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000007180 physiological regulation Effects 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220047090 rs6152 Human genes 0.000 description 2
- 208000002034 secondary hypertrophic osteoarthropathy Diseases 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 229960005460 teriparatide Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- MFOOVZCXWVAWOV-RUZDIDTESA-N (3r)-5-[2-(8-azaspiro[4.5]decane-8-carbonyl)-4,6-dimethylanilino]-3-naphthalen-1-yl-5-oxopentanoic acid Chemical compound C=1C(C)=CC(C)=C(NC(=O)C[C@H](CC(O)=O)C=2C3=CC=CC=C3C=CC=2)C=1C(=O)N(CC1)CCC21CCCC2 MFOOVZCXWVAWOV-RUZDIDTESA-N 0.000 description 1
- FJCZHMXAGBYXHJ-QGZVFWFLSA-N (4r)-5-(8-azaspiro[4.5]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid Chemical compound N([C@H](CCC(=O)O)C(=O)N1CCC2(CCCC2)CC1)C(=O)C1=CC(Cl)=CC(Cl)=C1 FJCZHMXAGBYXHJ-QGZVFWFLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RGGLEJFUEMKQSH-UHFFFAOYSA-N 1,4-benzodiazepin-2-one Chemical group O=C1C=NC=C2C=CC=CC2=N1 RGGLEJFUEMKQSH-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
- KOLPMNSDISYEBU-WJOKGBTCSA-N 2-[(3r)-1-(2,2-diethoxyethyl)-3-[(4-methylphenyl)carbamoylamino]-2-oxoindol-3-yl]-n-(4-methylphenyl)acetamide Chemical compound C([C@]1(NC(=O)NC=2C=CC(C)=CC=2)C(=O)N(C2=CC=CC=C21)CC(OCC)OCC)C(=O)NC1=CC=C(C)C=C1 KOLPMNSDISYEBU-WJOKGBTCSA-N 0.000 description 1
- PUMGFEMNXBLDKD-UHFFFAOYSA-N 3,6-diaminoacridine-9-carbonitrile Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C(C#N)=C21 PUMGFEMNXBLDKD-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010072395 Atypical fracture Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 1
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 1
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001416505 Mastomys Species 0.000 description 1
- 241000700167 Mastomys natalensis Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- IEKOTSCYBBDIJC-UHFFFAOYSA-N N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine Chemical compound CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 IEKOTSCYBBDIJC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000033793 Neuroendocrine tumor of stomach Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000015197 Pancoast syndrome Diseases 0.000 description 1
- 201000010630 Pancoast tumor Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 1
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000875 Spinal Curvatures Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101150058700 Tph1 gene Proteins 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000002280 acid secreting cell Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000004221 bone function Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 230000000125 calcaemic effect Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 108010066264 gastrin 17 Proteins 0.000 description 1
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000000796 hypoacidity effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229950001743 itriglumide Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229950000165 lorglumide Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000004678 mucosal integrity Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017970 negative regulation of osteoblast differentiation Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 208000029985 osteonecrosis of the jaw Diseases 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002807 parathyroid gland hormone Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000026011 regulation of ossification Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229950011476 spiroglumide Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 208000036506 well differentiated low or intermediate grade gastric neuroendocrine tumor Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907980P | 2013-11-22 | 2013-11-22 | |
| US61/907,980 | 2013-11-22 | ||
| PCT/US2014/066832 WO2015077572A1 (en) | 2013-11-22 | 2014-11-21 | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160088891A KR20160088891A (ko) | 2016-07-26 |
| KR102254957B1 true KR102254957B1 (ko) | 2021-05-25 |
Family
ID=52118000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167015759A Active KR102254957B1 (ko) | 2013-11-22 | 2014-11-21 | 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10709714B2 (enExample) |
| EP (1) | EP3071206B1 (enExample) |
| JP (1) | JP6502939B2 (enExample) |
| KR (1) | KR102254957B1 (enExample) |
| CN (1) | CN106163527A (enExample) |
| AU (1) | AU2014352875B2 (enExample) |
| BR (1) | BR112016011727A2 (enExample) |
| CA (1) | CA2929858C (enExample) |
| DK (1) | DK3071206T3 (enExample) |
| ES (1) | ES2870538T3 (enExample) |
| MX (1) | MX2016006657A (enExample) |
| PL (1) | PL3071206T3 (enExample) |
| RU (1) | RU2693484C1 (enExample) |
| WO (1) | WO2015077572A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10881667B2 (en) | 2018-10-30 | 2021-01-05 | City University Of Hong Kong | Method and composition for treating epilepsy |
| US11285161B2 (en) | 2019-04-26 | 2022-03-29 | City University Of Hong Kong | Method and composition for treating mental disorder and pain associated with nerve damage |
| CN110935005A (zh) * | 2019-11-19 | 2020-03-31 | 宁波大学 | 一种丙谷二肽的新用途 |
| CN115770266B (zh) * | 2023-01-30 | 2023-05-09 | 云南中医药大学 | 一种用于治疗绝经后骨质疏松的药物组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993012817A1 (en) | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| WO2005007107A2 (en) | 2003-07-11 | 2005-01-27 | University Of Massachusetts | Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4992437A (en) * | 1987-12-22 | 1991-02-12 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compounds and their pharmaceutical use |
| DE69017302T3 (de) | 1989-08-04 | 1999-08-05 | Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire | Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. |
| US5399565A (en) | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
| AU656754B2 (en) | 1990-12-25 | 1995-02-16 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzodiazepine derivative |
| CA2110986A1 (en) | 1991-07-12 | 1993-01-21 | Geoffrey Neil Woodruff | Cholecystokinin antagonists useful in the treatment of panic attacks |
| JP3239364B2 (ja) * | 1991-10-11 | 2001-12-17 | ウェルファイド株式会社 | 骨粗鬆症治療薬およびジアゼピン化合物 |
| IL104853A (en) | 1992-02-27 | 1997-11-20 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them |
| JP3419539B2 (ja) | 1993-02-17 | 2003-06-23 | 中外製薬株式会社 | インドリン−２−オン誘導体 |
| GB2282595A (en) | 1993-08-25 | 1995-04-12 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives |
| IT1261255B (it) | 1993-09-09 | 1996-05-09 | Rotta Research Lab | Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico. |
| WO1997021731A1 (en) | 1995-12-11 | 1997-06-19 | New England Medical Center Hospitals, Inc. | Assay for and uses of peptide hormone receptor ligands |
| US5750353A (en) | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
| US5922883A (en) | 1996-04-03 | 1999-07-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6548066B1 (en) | 1997-05-12 | 2003-04-15 | Aphton Corporation | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
| US20040001842A1 (en) | 1997-05-12 | 2004-01-01 | Dov Michaeli | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
| DK1076561T3 (da) | 1998-05-15 | 2005-06-06 | Aphton Corp | Kombinationsterapi til behandlingen af tumorer |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| WO1999062908A2 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| ES2228451T3 (es) | 1999-01-29 | 2005-04-16 | Chugai Seiyaku Kabushiki Kaisha | Promotores de condrogenesis y derivados de indolin-2-ona. |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US20030191279A1 (en) | 1999-08-27 | 2003-10-09 | Goldstein Steven Wayne | Urea derivatives useful as anticancer agents |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| PL200167B1 (pl) | 1999-11-05 | 2008-12-31 | Sod Conseils Rech Applic | Związki heterocykliczne o aktywności hamowania kalpain i/lub pułapkowania ROS, ich zastosowanie i kompozycje farmaceutyczne je zawierające oraz związki pośrednie |
| EP1229925A2 (en) | 1999-11-19 | 2002-08-14 | Axxima Pharmaceuticals Aktiengesellschaft | Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| WO2001077685A2 (en) | 2000-04-10 | 2001-10-18 | The General Hospital Corporation | Diagnosis and treatment of gastrointestinal disease |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| JP2005508838A (ja) | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
| WO2002087620A1 (en) | 2001-04-27 | 2002-11-07 | Chugai Seiyaku Kabushiki Kaisha | Chondrogenesis promoters |
| US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| US20040138207A1 (en) | 2001-05-11 | 2004-07-15 | Mayumi Yamano | Antitumor agents |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| ATE293449T1 (de) | 2001-11-13 | 2005-05-15 | Black James Foundation | Benzotriazepine als gastrin und cholecystokinin rezeptor liganden |
| ATE353013T1 (de) | 2002-02-19 | 2007-02-15 | Pfizer Italia Srl | Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel |
| DE10207037A1 (de) | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| UA79804C2 (en) | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
| US20030049698A1 (en) | 2002-10-08 | 2003-03-13 | Wang Timothy C. | Diagnosis and treatment of gastrointestinal disease |
| UA82872C2 (en) | 2003-03-28 | 2008-05-26 | Janssen Pharmaceutica Nv | Benzo [1,2,5] thiadiazole compounds |
| GB0310865D0 (en) | 2003-05-12 | 2003-06-18 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| WO2004101533A1 (en) | 2003-05-12 | 2004-11-25 | Janssen Pharmaceutica, N.V. | 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands |
| HRP20080559T3 (hr) | 2003-08-08 | 2009-01-31 | Janssen Pharmaceutica N.V. | 2-(kinoksalin-5-ilsulfonilamino)-benzamidni spojevi kao regulatori cck2 |
| WO2005090319A1 (en) | 2004-03-19 | 2005-09-29 | Arrow Therapeutics Limited | Process for preparing benzodiazepines |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7947833B2 (en) | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| AU2005289887A1 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
| US20080124741A1 (en) | 2004-10-12 | 2008-05-29 | Heng Dai | Canine Cholecystokinin 1 Receptor Materials And Their Use |
| EP1804785A2 (en) | 2004-10-27 | 2007-07-11 | Neurogen Corporation | Diaryl ureas as cb1 antagonists |
| CA2579227A1 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as cb1 antagonists |
| GB0425196D0 (en) | 2004-11-15 | 2004-12-15 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| EA011512B1 (ru) | 2004-12-17 | 2009-04-28 | Ракуалиа Фарма Инк. | Производные хромана, полезные в качестве антагонистов кислотной помпы |
| PT1839662E (pt) | 2005-01-19 | 2010-04-28 | Zeria Pharm Co Ltd | Agente antitumoral |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| JP5197361B2 (ja) | 2005-06-06 | 2013-05-15 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | 睡眠障害を処置するための組成物および方法 |
| EP1893197B1 (en) | 2005-06-14 | 2009-09-09 | RaQualia Pharma Inc | Chromane substituted benzimidazole derivatives as acid pump antagonists |
| ATE425791T1 (de) | 2005-07-29 | 2009-04-15 | Rottapharm Spa | Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten |
| WO2007026218A2 (en) | 2005-09-01 | 2007-03-08 | Pfizer Japan Inc. | Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists |
| WO2007031860A1 (en) | 2005-09-15 | 2007-03-22 | Pfizer Japan Inc. | Indane substituted benzimidazoles and their use as acid pump inhibitors |
| BRPI0620081B8 (pt) | 2005-12-19 | 2021-05-25 | Pfizer | composto e composição farmacêutica. |
| WO2007072142A2 (en) | 2005-12-19 | 2007-06-28 | Pfizer Japan Inc. | Benzimidazole-5-carboxamide derivatives |
| CA2645007A1 (en) | 2006-03-17 | 2007-09-27 | Raqualia Pharma Inc. | Chromane derivatives |
| JP2009533362A (ja) | 2006-04-12 | 2009-09-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼ媒介性疾患を治療するための複素環式置換ビスアリール尿素のｎ−オキシド |
| FR2901473B1 (fr) | 2006-05-24 | 2010-08-13 | Oreal | Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide |
| FR2901472B1 (fr) | 2006-05-24 | 2010-08-13 | Oreal | Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants |
| KR101109866B1 (ko) | 2006-09-21 | 2012-04-12 | 라퀄리아 파마 인코포레이티드 | 선택성 산 펌프 억제제로서의 벤즈이미다졸 유도체 |
| WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
| WO2008059373A1 (en) | 2006-11-17 | 2008-05-22 | Raqualia Pharma Inc. | Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| WO2008114123A1 (en) | 2007-03-21 | 2008-09-25 | Raqualia Pharma Inc. | Spiro benzimidazole derivatives as acid pump inhibitors |
| WO2008124518A1 (en) | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| WO2008124524A2 (en) | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Aryl sulfonamide compounds as modulators of the cck2 receptor |
| WO2009000413A1 (en) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| RU2379043C2 (ru) | 2007-08-02 | 2010-01-20 | Закрытое акционерное общество "Биологические исследования и системы" | Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы |
| WO2009020768A1 (en) | 2007-08-07 | 2009-02-12 | President And Fellows Of Harvard College | Targeting the oncoprotein nucleophosmin |
| AR073578A1 (es) | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| SG174591A1 (en) | 2009-03-31 | 2011-10-28 | Zeria Pharm Co Ltd | Method for manufacturing 1,5-benzodiazepine derivative |
| JP5802898B2 (ja) | 2009-07-09 | 2015-11-04 | ラクオリア創薬株式会社 | 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤 |
| EP2480549B1 (en) | 2009-09-24 | 2015-04-08 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Fused imidazo[3,2-d]pyrazines as PI3 kinase inhibitors |
| IN2012DN03883A (enExample) | 2009-10-06 | 2015-09-25 | Millennium Pharm Inc | |
| WO2011060304A2 (en) | 2009-11-13 | 2011-05-19 | Constar International, Inc. | Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions |
| WO2011063164A2 (en) | 2009-11-18 | 2011-05-26 | Steady Sleep Rx Co., Inc. | Sustained release cannabinoid medicaments |
| KR20130069640A (ko) | 2010-04-23 | 2013-06-26 | 키네타, 인크. | 항-바이러스 화합물 |
| EP2603098B1 (en) | 2010-08-12 | 2025-08-06 | Firmenich Incorporated | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer |
| EP2640379A4 (en) | 2010-11-18 | 2014-08-13 | Pier Pharmaceuticals | LOW DOSED CANNABINOIDARY MEDICINES |
| US20120231083A1 (en) | 2010-11-18 | 2012-09-13 | The Board Of Trustees Of The University Of Illinois | Sustained release cannabinoid medicaments |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| RU2634708C9 (ru) | 2011-11-07 | 2018-05-11 | Массачусетс Инститьют Оф Текнолоджи | Оксоалкилиденовые комплексы вольфрама для z-селективного метатезиса олефинов |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
-
2014
- 2014-11-21 RU RU2016124538A patent/RU2693484C1/ru active
- 2014-11-21 AU AU2014352875A patent/AU2014352875B2/en active Active
- 2014-11-21 ES ES14815149T patent/ES2870538T3/es active Active
- 2014-11-21 KR KR1020167015759A patent/KR102254957B1/ko active Active
- 2014-11-21 MX MX2016006657A patent/MX2016006657A/es unknown
- 2014-11-21 CN CN201480073822.0A patent/CN106163527A/zh active Pending
- 2014-11-21 JP JP2016533607A patent/JP6502939B2/ja active Active
- 2014-11-21 US US14/550,233 patent/US10709714B2/en active Active
- 2014-11-21 WO PCT/US2014/066832 patent/WO2015077572A1/en not_active Ceased
- 2014-11-21 EP EP14815149.1A patent/EP3071206B1/en active Active
- 2014-11-21 PL PL14815149T patent/PL3071206T3/pl unknown
- 2014-11-21 BR BR112016011727A patent/BR112016011727A2/pt not_active Application Discontinuation
- 2014-11-21 DK DK14815149.1T patent/DK3071206T3/da active
- 2014-11-21 CA CA2929858A patent/CA2929858C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993012817A1 (en) | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| WO2005007107A2 (en) | 2003-07-11 | 2005-01-27 | University Of Massachusetts | Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016124538A (ru) | 2017-12-27 |
| CA2929858C (en) | 2022-03-29 |
| US20150148339A1 (en) | 2015-05-28 |
| US10709714B2 (en) | 2020-07-14 |
| RU2693484C1 (ru) | 2019-07-03 |
| EP3071206B1 (en) | 2021-02-17 |
| EP3071206A1 (en) | 2016-09-28 |
| BR112016011727A2 (pt) | 2017-08-08 |
| PL3071206T3 (pl) | 2022-01-17 |
| CA2929858A1 (en) | 2015-05-28 |
| WO2015077572A1 (en) | 2015-05-28 |
| JP6502939B2 (ja) | 2019-04-17 |
| DK3071206T3 (da) | 2021-05-25 |
| CN106163527A (zh) | 2016-11-23 |
| MX2016006657A (es) | 2016-10-12 |
| AU2014352875A8 (en) | 2016-06-30 |
| AU2014352875A1 (en) | 2016-05-26 |
| KR20160088891A (ko) | 2016-07-26 |
| AU2014352875B2 (en) | 2019-10-24 |
| JP2016538295A (ja) | 2016-12-08 |
| ES2870538T3 (es) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lesclous et al. | Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? | |
| Salari Sharif et al. | Current, new and future treatments of osteoporosis | |
| Makhoul et al. | The best of both worlds—managing the cancer, saving the bone | |
| KR102254957B1 (ko) | 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드) | |
| Xu et al. | Effects of different dosages of parathyroid hormone-related protein 1–34 on the bone metabolism of the ovariectomized rat model of osteoporosis | |
| Di Bella et al. | Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report | |
| US11135212B2 (en) | Method for treating osteoporosis, osteopenia or low bone mineral density | |
| Abo-Elenin et al. | An overview of osteoporosis and possible treatment approaches | |
| Zwolak et al. | Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone | |
| Vashghani Farahani et al. | The effects of pentoxifylline adminstration on fracture healing in a postmenopausal osteoporotic rat model | |
| McDonald et al. | Bisphosphonate treatment and fracture repair | |
| CN102935079A (zh) | 咖啡酸3,4-二羟基苯乙酯的制药用途 | |
| Yoshii et al. | Local application of a proteasome inhibitor enhances fracture healing in rats | |
| Goel et al. | 9-Demethoxy-medicarpin promotes peak bone mass achievement and has bone conserving effect in ovariectomized mice: Positively regulates osteoblast functions and suppresses osteoclastogenesis | |
| HK1230487A1 (en) | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis | |
| Abo-Rayah et al. | Forskolin Could Protect Against Flutamide-Induced Osteoporosis By Modulation of Serum Osteocalcin and Sclerostin In Rats | |
| US9273006B2 (en) | Anabolic compounds for treating and preventing bone loss diseases | |
| Mohanty et al. | Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review | |
| Ballon-Landa et al. | Management of bone complications in patients with genitourinary malignancies | |
| Liu et al. | An evodiamine derivative inhibits osteoclast differentiation and protects against OVX‐induced bone loss in mice | |
| Canuas Landero | Defining how oestrogen influences the anti-tumour effects of adjuvant bisphosphonates using in vivo models of breast cancer | |
| Xiong et al. | Quercetin alleviates osteoporosis in rat mandibles induced by ovariectomy through modulation of autophagy and inhibition of NLRP3 pathway | |
| Fasipe et al. | Osteoporosis Now and in the Future: The Role of Newer Emerging Agents in the Management of Osteoporotic Bone Diseases–A Review | |
| Hershman et al. | Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer | |
| Peyruchaud et al. | Lysophosphatidic Acid (LPA) Signaling and Bone Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160614 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20191106 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200804 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210216 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210517 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210518 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |